Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia

Estrogen (E) treatment has proven to be effective in preventing bone loss after menopause with, however, some undesirable side effects. Many of these side effects are related to the hormone's actions on reproductive tissues. Raloxifene is an organ-selective estrogen agonist that prevents acute...

Full description

Saved in:
Bibliographic Details
Published in:Endocrinology (Philadelphia) 1996-10, Vol.137 (10), p.4139-4144
Main Authors: Evans, G L, Bryant, H U, Magee, D E, Turner, R T
Format: Article
Language:English
Subjects:
Agonists
Animals
Atrophy
Body weight
Bone and Bones - metabolism
Bone Diseases, Metabolic - prevention & control
Bone growth
Bone loss
Bone turnover
Cancellous bone
Cholesterol
Dose-response effects
Dose-Response Relationship, Drug
Estrogen Antagonists - pharmacology
Estrogen receptors
Estrogens
Ethinyl Estradiol - pharmacology
Female
Menopause
Osteopenia
Ovariectomy
Piperidines - pharmacology
Raloxifene
Raloxifene Hydrochloride
Rats
Rats, Sprague-Dawley
Side effects
Skeleton
Space life sciences
Uterus
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Estrogen (E) treatment has proven to be effective in preventing bone loss after menopause with, however, some undesirable side effects. Many of these side effects are related to the hormone's actions on reproductive tissues. Raloxifene is an organ-selective estrogen agonist that prevents acute cancellous osteopenia in ovariectomized (OVX'd) growing rats. The effects of raloxifene on adult rats with established bone loss are not known. We now compare the dose response effects of 4 months of treatment with raloxifene and estrogen in 8-month-old rats that had been OVX'd 2 months before treatment. OVX resulted in increased body weight, uterine atrophy and severe cancellous bone loss. Estrogen resulted in a dose-dependent increase in uterine weight in OVX'd rats whereas raloxifene did not promote uterine growth. Both treatments reduced body weight and serum cholesterol. Raloxifene and estrogen were each effective in stabilizing cancellous bone by preventing additional cancellous bone loss, but neither treatment replaced lost bone. These findings provide further evidence that raloxifene is a much more potent estrogen agonist on the skeleton and liver than on the uterus.
ISSN:0013-7227
1945-7170
DOI:10.1210/en.137.10.4139